| Charles Christopher Edwards, DPM | |
|
4315 Diplomacy Drive, Anchorage, AK 99508-5926 | |
| (907) 729-1500 | |
| (907) 729-2082 |
| Full Name | Charles Christopher Edwards |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 25 Years |
| Location | 4315 Diplomacy Drive, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447291067 | NPI | - | NPPES |
| PD26281 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 5109 (Alaska) | Secondary |
| 213E00000X | Podiatrist | 5109 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alaska Native Medical Center | Anchorage, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alaska Native Tribal Health Consortium | 6709780265 | 457 |
| Yukon-kuskokwim Health Corporation | 5193718765 | 77 |
News Archive
3D Signatures Inc. is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HL, 3DS' test in development for Hodgkin's lymphoma (HL), shows that the Company's TeloViewTM platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months.
State-of-the art treatments for patients with heart problems are the theme of a public lecture at the University of Greenwich this month. The lecture, which is free and open to all, will look at the role of stents in treating coronary artery diseases. A stent is a tiny, artificial tube which is placed in the coronary arteries that supply the heart: by keeping the arteries open, the stent combats the effects of reduced blood flow, such as blood clots.
Health providers may experience information and financial loss during the mandated conversion from the current International Classification of Diseases to its new and improved version, report researchers at the University of Illinois at Chicago.
Keck Medicine of the University of Southern California scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth. The protein, GPR158, was found while the researchers were looking for new drug targets for glaucoma.
› Verified 4 days ago
| Entity Name | Southeast Alaska Regional Health Consortium |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376758037 PECOS PAC ID: 1456265362 Enrollment ID: O20031114000631 |
News Archive
3D Signatures Inc. is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HL, 3DS' test in development for Hodgkin's lymphoma (HL), shows that the Company's TeloViewTM platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months.
State-of-the art treatments for patients with heart problems are the theme of a public lecture at the University of Greenwich this month. The lecture, which is free and open to all, will look at the role of stents in treating coronary artery diseases. A stent is a tiny, artificial tube which is placed in the coronary arteries that supply the heart: by keeping the arteries open, the stent combats the effects of reduced blood flow, such as blood clots.
Health providers may experience information and financial loss during the mandated conversion from the current International Classification of Diseases to its new and improved version, report researchers at the University of Illinois at Chicago.
Keck Medicine of the University of Southern California scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth. The protein, GPR158, was found while the researchers were looking for new drug targets for glaucoma.
› Verified 4 days ago
| Entity Name | Alaska Native Tribal Health Consortium |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437189339 PECOS PAC ID: 6709780265 Enrollment ID: O20031125000772 |
News Archive
3D Signatures Inc. is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HL, 3DS' test in development for Hodgkin's lymphoma (HL), shows that the Company's TeloViewTM platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months.
State-of-the art treatments for patients with heart problems are the theme of a public lecture at the University of Greenwich this month. The lecture, which is free and open to all, will look at the role of stents in treating coronary artery diseases. A stent is a tiny, artificial tube which is placed in the coronary arteries that supply the heart: by keeping the arteries open, the stent combats the effects of reduced blood flow, such as blood clots.
Health providers may experience information and financial loss during the mandated conversion from the current International Classification of Diseases to its new and improved version, report researchers at the University of Illinois at Chicago.
Keck Medicine of the University of Southern California scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth. The protein, GPR158, was found while the researchers were looking for new drug targets for glaucoma.
› Verified 4 days ago
| Entity Name | Yukon-kuskokwim Health Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447477815 PECOS PAC ID: 5193718765 Enrollment ID: O20040407001515 |
News Archive
3D Signatures Inc. is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HL, 3DS' test in development for Hodgkin's lymphoma (HL), shows that the Company's TeloViewTM platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months.
State-of-the art treatments for patients with heart problems are the theme of a public lecture at the University of Greenwich this month. The lecture, which is free and open to all, will look at the role of stents in treating coronary artery diseases. A stent is a tiny, artificial tube which is placed in the coronary arteries that supply the heart: by keeping the arteries open, the stent combats the effects of reduced blood flow, such as blood clots.
Health providers may experience information and financial loss during the mandated conversion from the current International Classification of Diseases to its new and improved version, report researchers at the University of Illinois at Chicago.
Keck Medicine of the University of Southern California scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth. The protein, GPR158, was found while the researchers were looking for new drug targets for glaucoma.
› Verified 4 days ago
| Entity Name | Kodiak Area Native Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679514236 PECOS PAC ID: 8426959297 Enrollment ID: O20041004000838 |
News Archive
3D Signatures Inc. is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HL, 3DS' test in development for Hodgkin's lymphoma (HL), shows that the Company's TeloViewTM platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months.
State-of-the art treatments for patients with heart problems are the theme of a public lecture at the University of Greenwich this month. The lecture, which is free and open to all, will look at the role of stents in treating coronary artery diseases. A stent is a tiny, artificial tube which is placed in the coronary arteries that supply the heart: by keeping the arteries open, the stent combats the effects of reduced blood flow, such as blood clots.
Health providers may experience information and financial loss during the mandated conversion from the current International Classification of Diseases to its new and improved version, report researchers at the University of Illinois at Chicago.
Keck Medicine of the University of Southern California scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth. The protein, GPR158, was found while the researchers were looking for new drug targets for glaucoma.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles Christopher Edwards, DPM 4315 Diplomacy Drive, Anchorage, AK 99508-5926 Ph: (907) 729-1500 | Charles Christopher Edwards, DPM 4315 Diplomacy Drive, Anchorage, AK 99508-5926 Ph: (907) 729-1500 |
News Archive
3D Signatures Inc. is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HL, 3DS' test in development for Hodgkin's lymphoma (HL), shows that the Company's TeloViewTM platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months.
State-of-the art treatments for patients with heart problems are the theme of a public lecture at the University of Greenwich this month. The lecture, which is free and open to all, will look at the role of stents in treating coronary artery diseases. A stent is a tiny, artificial tube which is placed in the coronary arteries that supply the heart: by keeping the arteries open, the stent combats the effects of reduced blood flow, such as blood clots.
Health providers may experience information and financial loss during the mandated conversion from the current International Classification of Diseases to its new and improved version, report researchers at the University of Illinois at Chicago.
Keck Medicine of the University of Southern California scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth. The protein, GPR158, was found while the researchers were looking for new drug targets for glaucoma.
› Verified 4 days ago